Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Down 42.6% in November

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 274,500 shares, a decline of 42.6% from the October 31st total of 478,400 shares. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.77% of Quoin Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 8.63% of the stock is currently owned by institutional investors and hedge funds.

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ QNRX remained flat at $0.60 during midday trading on Thursday. The company had a trading volume of 36,627 shares, compared to its average volume of 919,008. The company has a market capitalization of $3.03 million, a PE ratio of -0.15 and a beta of 1.85. Quoin Pharmaceuticals has a 52-week low of $0.48 and a 52-week high of $6.18. The company’s 50-day moving average is $0.63 and its two-hundred day moving average is $0.64.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.